Redefining Innovation with Bayesian Statistics
Inspired by Thomas Bayes, we transform uncertainty into opportunity for modern clinical development.
Discover Our Solutions"It is possible to calculate rational degrees of belief from incomplete information."
Cogitars - The Bayesian Experts!
Specialized statistical support for innovative development in pharmaceuticals, medical devices, and diagnostics.
Bayesian Statistics for Dose Escalation
We offer model-based approaches for dose escalation studies, including optimization and Bayesian decision rules for Phase 3 studies. Our methods have been proven to work in practice across numerous clinical trials.
Bayesian Statistics for Dose Optimization (Project Optimus)
We support FDA’s Project Optimus with model-based dose optimization using Bayesian methods, integrating pharmacokinetics, pharmacodynamics, efficacy, and safety to identify optimal, patient-centered dosing.
Bayesian decision rules for Phase 2/3 studies.
We implement Bayesian decision-making frameworks in Phase 2 and 3 trials to enable early, data-driven go/no-go decisions. By incorporating efficacy, safety, and prior evidence, our methods improve trial efficiency and support more informed development strategies..
Statistical Support for Clinical Trials including Estimand framework
Comprehensive statistical support for Phase 1/2 and 3 studies, helping biotechnology companies make better use of their data to improve the development of their compounds.
Visual Trial Monitoring & Reporting
Advanced visual trial monitoring and reporting using Python/R and AI technologies, providing real-time insights and data visualization for clinical operations teams. And report generation with CDISC Standards (SDTM and ADAM)
DMC/DSMB/HTA Support
Expert Data (Safety) Monitoring Board (DMC/DSMB) support with extensive experience across different indications, ensuring proper safety oversight for your clinical trials. Supporting your HTA dossier with robust, transparent, and scientifically grounded statistical methodology. We ensure that your evidence package stands up to scrutiny by integrating best-in-class statistical approaches tailored to payer expectations.